IBDEI0PC ; ; 20-MAY-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;OCT 15, 2014
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,12422,1,8,0)
 ;;=8^C L L,W/O Remission
 ;;^UTILITY(U,$J,358.3,12422,2)
 ;;=^267523
 ;;^UTILITY(U,$J,358.3,12423,0)
 ;;=204.11^^70^759^4
 ;;^UTILITY(U,$J,358.3,12423,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,12423,1,1,0)
 ;;=1^204.11
 ;;^UTILITY(U,$J,358.3,12423,1,8,0)
 ;;=8^C L L,In Remission
 ;;^UTILITY(U,$J,358.3,12423,2)
 ;;=^267524
 ;;^UTILITY(U,$J,358.3,12424,0)
 ;;=201.90^^70^759^8
 ;;^UTILITY(U,$J,358.3,12424,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,12424,1,1,0)
 ;;=1^201.90
 ;;^UTILITY(U,$J,358.3,12424,1,8,0)
 ;;=8^Hodgkins Lymphoma,Unspec Type
 ;;^UTILITY(U,$J,358.3,12424,2)
 ;;=^267430
 ;;^UTILITY(U,$J,358.3,12425,0)
 ;;=202.00^^70^759^14
 ;;^UTILITY(U,$J,358.3,12425,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,12425,1,1,0)
 ;;=1^202.00
 ;;^UTILITY(U,$J,358.3,12425,1,8,0)
 ;;=8^Lymphoma, Low-Grade (Nodular)
 ;;^UTILITY(U,$J,358.3,12425,2)
 ;;=^72606
 ;;^UTILITY(U,$J,358.3,12426,0)
 ;;=200.20^^70^759^15
 ;;^UTILITY(U,$J,358.3,12426,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,12426,1,1,0)
 ;;=1^200.20
 ;;^UTILITY(U,$J,358.3,12426,1,8,0)
 ;;=8^Lymphoma,Burkitts
 ;;^UTILITY(U,$J,358.3,12426,2)
 ;;=^17529
 ;;^UTILITY(U,$J,358.3,12427,0)
 ;;=202.10^^70^759^23
 ;;^UTILITY(U,$J,358.3,12427,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,12427,1,1,0)
 ;;=1^202.10
 ;;^UTILITY(U,$J,358.3,12427,1,8,0)
 ;;=8^Mycosis Fungoides
 ;;^UTILITY(U,$J,358.3,12427,2)
 ;;=^80360
 ;;^UTILITY(U,$J,358.3,12428,0)
 ;;=273.3^^70^759^19
 ;;^UTILITY(U,$J,358.3,12428,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,12428,1,1,0)
 ;;=1^273.3
 ;;^UTILITY(U,$J,358.3,12428,1,8,0)
 ;;=8^Macroglobulinemia
 ;;^UTILITY(U,$J,358.3,12428,2)
 ;;=^73013
 ;;^UTILITY(U,$J,358.3,12429,0)
 ;;=203.00^^70^759^22
 ;;^UTILITY(U,$J,358.3,12429,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,12429,1,1,0)
 ;;=1^203.00
 ;;^UTILITY(U,$J,358.3,12429,1,8,0)
 ;;=8^Multiple Myeloma,W/O Remission
 ;;^UTILITY(U,$J,358.3,12429,2)
 ;;=^267514
 ;;^UTILITY(U,$J,358.3,12430,0)
 ;;=203.01^^70^759^21
 ;;^UTILITY(U,$J,358.3,12430,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,12430,1,1,0)
 ;;=1^203.01
 ;;^UTILITY(U,$J,358.3,12430,1,8,0)
 ;;=8^Multiple Myeloma,In Remission
 ;;^UTILITY(U,$J,358.3,12430,2)
 ;;=^267515
 ;;^UTILITY(U,$J,358.3,12431,0)
 ;;=202.40^^70^759^7
 ;;^UTILITY(U,$J,358.3,12431,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,12431,1,1,0)
 ;;=1^202.40
 ;;^UTILITY(U,$J,358.3,12431,1,8,0)
 ;;=8^Hairy-Cell Leukemia
 ;;^UTILITY(U,$J,358.3,12431,2)
 ;;=^69587
 ;;^UTILITY(U,$J,358.3,12432,0)
 ;;=200.10^^70^759^17
 ;;^UTILITY(U,$J,358.3,12432,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,12432,1,1,0)
 ;;=1^200.10
 ;;^UTILITY(U,$J,358.3,12432,1,8,0)
 ;;=8^Lymphoma,Int/High (Diffuse)
 ;;^UTILITY(U,$J,358.3,12432,2)
 ;;=^175886
 ;;^UTILITY(U,$J,358.3,12433,0)
 ;;=273.1^^70^759^20
 ;;^UTILITY(U,$J,358.3,12433,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,12433,1,1,0)
 ;;=1^273.1
 ;;^UTILITY(U,$J,358.3,12433,1,8,0)
 ;;=8^Monoclon Paraproteinemia
 ;;^UTILITY(U,$J,358.3,12433,2)
 ;;=^78888
 ;;^UTILITY(U,$J,358.3,12434,0)
 ;;=238.79^^70^759^18
 ;;^UTILITY(U,$J,358.3,12434,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,12434,1,1,0)
 ;;=1^238.79
 ;;^UTILITY(U,$J,358.3,12434,1,8,0)
 ;;=8^Lymphoproliferat Dis
 ;;^UTILITY(U,$J,358.3,12434,2)
 ;;=^334033
 ;;^UTILITY(U,$J,358.3,12435,0)
 ;;=202.90^^70^759^16
 ;;^UTILITY(U,$J,358.3,12435,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,12435,1,1,0)
 ;;=1^202.90
 ;;^UTILITY(U,$J,358.3,12435,1,8,0)
 ;;=8^Lymphoma,Diffuse,Unspec Site
 ;;^UTILITY(U,$J,358.3,12435,2)
 ;;=^267504
 ;;^UTILITY(U,$J,358.3,12436,0)
 ;;=205.01^^70^759^3
